Boston Scientific Co. (NYSE:BSX) EVP David A. Pierce sold 5,140 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $38.45, for a total transaction of $197,633.00. Following the completion of the sale, the executive vice president now directly owns 27,173 shares of the company’s stock, valued at $1,044,801.85. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Shares of Boston Scientific stock traded up $1.05 during mid-day trading on Friday, reaching $42.98. 12,753,700 shares of the stock were exchanged, compared to its average volume of 7,769,971. The company has a market capitalization of $58.52 billion, a P/E ratio of 29.24, a price-to-earnings-growth ratio of 2.45 and a beta of 0.75. The company has a current ratio of 1.39, a quick ratio of 1.12 and a debt-to-equity ratio of 0.82. The company has a 50-day simple moving average of $39.43. Boston Scientific Co. has a fifty-two week low of $31.56 and a fifty-two week high of $43.02.
Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 24th. The medical equipment provider reported $0.35 EPS for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.01). The company had revenue of $2.49 billion for the quarter, compared to the consensus estimate of $2.54 billion. Boston Scientific had a return on equity of 24.65% and a net margin of 18.08%. The firm’s revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.33 EPS. On average, equities research analysts expect that Boston Scientific Co. will post 1.55 EPS for the current fiscal year.
A number of analysts recently commented on BSX shares. Needham & Company LLC reiterated a “buy” rating and issued a $43.00 target price on shares of Boston Scientific in a report on Monday, May 13th. Canaccord Genuity cut their price target on shares of Boston Scientific from $45.00 to $43.00 and set a “buy” rating on the stock in a report on Wednesday, April 17th. Jefferies Financial Group boosted their price target on shares of Boston Scientific from $44.00 to $48.00 and gave the company a “positive” rating in a report on Thursday. Piper Jaffray Companies boosted their price target on shares of Boston Scientific from $42.00 to $50.00 and gave the company an “overweight” rating in a report on Thursday. Finally, BTIG Research reaffirmed a “buy” rating on shares of Boston Scientific in a research report on Thursday, April 25th. Four analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $43.63.
Boston Scientific Company Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Further Reading: Is the QQQ ETF safe?
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.